This collaboration aims to improve patient safety and accelerate the development of new therapies by addressing a leading cause of failure in clinical trials. The goal is to develop more streamlined, scalable, and genetically diverse liver organoid technology as a drug toxicity screening solution, so that the biopharma industry is better-positioned be able to deliver better, safer drugs to patients faster. 

This partnership is developing a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year. The test will leverage rapid molecular diagnostic technologies to pinpoint different subtypes of sepsis and allow the development of novel personalized care paths, including which targeted therapies are most likely to help. 

This Beacon focuses on innovation at the intersection of biology and manufacturing, with the long-term goal of fully realizing the promise of gene therapy. It aims to deliver product solutions that address bottlenecks impacting viral vector manufacturing yield and quality.